Evidence map›Paper›PMID 38837988›Full record

ArticlePloS one2024

Data driven approach to characterize rapid decline in autosomal dominant polycystic kidney disease.

John J Sim, Yu-Hsiang Shu, Simran K Bhandari, Qiaoling Chen, Teresa N Harrison, Min Young Lee, Mercedes A Munis, Kerresa Morrissette, Shirin Sundar, Kristin Pareja and 2 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

John J SimDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States of America.ORCID 0000-0001-9456-8243
Yu-Hsiang ShuBiostatistics and Programming Clinical Affairs, Inari Medical, Irvine, CA, United States of America.
Simran K BhandariDepartment of Internal Medicine, Bellflower Medical Center, Bellflower, CA, United States of America.
Qiaoling ChenDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States of America.
Teresa N HarrisonDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States of America.ORCID 0000-0002-7827-7654
Min Young LeeDivision of Nephrology and Hypertension, Kaiser Permanente Los Angeles Medical Center, Los Angeles, CA, United States of America.
Mercedes A MunisDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States of America.
Kerresa MorrissetteDepartment of Research & Evaluation, Kaiser Permanente Southern California, Pasadena, CA, United States of America.ORCID 0000-0002-8333-0405
Shirin SundarOtsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, United States of America.
Kristin ParejaOtsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, United States of America.
Ali NourbakhshOtsuka Pharmaceutical Development & Commercialization, Inc., Princeton, NJ, United States of America.
Cynthia J WilleyCollege of Pharmacy, University of Rhode Island, Kingston, RI, United States of America.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a genetic kidney disease with high phenotypic variability. Furthering insights into patients' ADPKD progression could lead to earlier detection, management, and alter the course to end stage kidney disease (ESKD). We sought to identify patients with rapid decline (RD) in kidney function and to determine clinical factors associated with RD using a data-driven approach. A retrospective cohort study was performed among patients with incident ADPKD (1/1/2002-12/31/2018). Latent class mixed models were used to identify RD patients using differences in eGFR trajectories over time. Predictors of RD were selected based on agreements among feature selection methods, including logistic, regularized, and random forest modeling. The final model was built on the selected predictors and clinically relevant covariates. Among 1,744 patients with incident ADPKD, 125 (7%) were identified as RD. Feature selection included 42 clinical measurements for adaptation with multiple imputations; mean (SD) eGFR was 85.2 (47.3) and 72.9 (34.4) in the RD and non-RD groups, respectively. Multiple imputed datasets identified variables as important features to distinguish RD and non-RD groups with the final prediction model determined as a balance between area under the curve (AUC) and clinical relevance which included 6 predictors: age, sex, hypertension, cerebrovascular disease, hemoglobin, and proteinuria. Results showed 72%-sensitivity, 70%-specificity, 70%-accuracy, and 0.77-AUC in identifying RD. 5-year ESKD rates were 38% and 7% among RD and non-RD groups, respectively. Using real-world routine clinical data among patients with incident ADPKD, we observed that six variables highly predicted RD in kidney function.

Indexed as

Disease ProgressionGlomerular Filtration RatePolycystic Kidney, Autosomal DominantAdultFemaleHumansKidneyKidney Failure, ChronicMaleMiddle AgedRetrospective Studies

Identifiers

PMID38837988
PMCPMC11152279

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.